BNTX ▲ +3.4% - BioNTech SE $BNTX - BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients BioNTech shares rose 3.4% following the presentation of updated trial data for its experimental cancer drug gotistobart, which demonstrated nearly double the median overall survival compared to standard chemotherapy in previously treated squamous non-small cell lung cancer patients. The positive efficacy results from the ongoing study support the clinical potential of the treatment candidate and may strengthen BioNTech's pipeline in the competitive oncology space. 14-SEP-2026 04:00 AM ET